HB

Hardikkumar Bharatbhai Shingala

Active Director Director DIN 11000386
DIN 11000386 First appointment Mar 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Hardikkumar Bharatbhai Shingala

Data last updated:

Hardikkumar Bharatbhai Shingala is a Director at Mediport Pharma Private Limited (since 2025). The company operates in Paper.

DIN 11000386
Primary Designation Director
Industry Paper
First Appointment 13 Mar 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Mediport Pharma Private Limited U21000GJ2025PTC160262
Director13 Mar 20252025Active

Board colleagues of Hardikkumar Bharatbhai Shingala

Directorship timeline

Open interactive timeline →
Mediport Pharma Private Limited
Premium access

Shareholding and investment profile for Hardikkumar Bharatbhai Shingala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hardikkumar Bharatbhai Shingala

Hardikkumar Bharatbhai Shingala currently holds 1 directorship: Mediport Pharma Private Limited (Director, since 13 Mar 2025).

Hardikkumar Bharatbhai Shingala was first appointed on 13 Mar 2025 as Director at Mediport Pharma Private Limited.

The current boards of Hardikkumar Bharatbhai Shingala's companies include Pradip Nathabhai Kanani (Mediport Pharma Private Limited), Vivek Dhanjibhai Gondaliya (Mediport Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available